ANTIPSYCHOTICS AND LOW VITAMIN D – ADDITIONAL DATA CALLING FOR DRUG CAUSALITY ASSESSMENT

SVETLANA RISTIC¹, DRAGAN MILOVANOVIC^{2,6*}, VLADIMIR JANJIC^{3,6},
MARIJANA STANOJEVIC PIRKOVIC^{4,6}, IVANA SIMIC VUKOMANOVIC^{5,7},
SVETLANA CURCIC⁸ and SANJA KOCIC^{5,7}

¹Institute for Oncology and Radiology of Serbia,

Department of Epidemiology and Prevention, Belgrade, Serbia

²Department of Pharmacology and Toxicology, ³Department of Psychiatry,

⁴Department of Biochemistry, ⁵Department of Social Medicine, Faculty of Medical Sciences,
University of Kragujevac, Serbia

⁶Clinical Centre “Kragujevac”, Kragujevac, Serbia

⁷Institute for Public Health Kragujevac, Serbia

⁸Faculty of Education in Jagodina, University of Kragujevac, Serbia

The recent systematic published findings suggest that patients with psychiatric disorders have an increased risk for lower serum vitamin D levels (1). However, the exact causes of this phenomenon and its relevance for clinical outcomes have not been fully explained yet. The population-level data suggest that there is a positive correlation between optimal serum levels of 25(OH)D and better mental health indicators (2). In addition, active vitamin D supplementation shows some improvements in the symptoms. However, it did not affect the course of psychosis in patients with chronic, antipsychotic-treated disease in double-blind, placebo-controlled clinical trial settings (3).

Antipsychotics could affect calcium, magnesium, phosphorous and 25(OH)D serum concentrations during treatment initiations as well as during dosage or drug changes (4). Disturbances in minerals and vitamins related to bone metabolism can lead to increased risks for fractures associated with the use of the first and the second generation of antipsychotic medication as was documented in a recent meta-analysis of the available data (5). However, the evidence base for a definite assessment of the possible causality relations between vitamin D disturbances and antipsychotic drugs remains insufficient. In addition, vitamin D levels and bone health may be under the effect of concomitant psychotropic drugs

affecting vitamin D metabolism such as mood stabilizers (6). Therefore, this study aimed at exploring 25(OH)D serum levels in patients with psychoses who take antipsychotics in comparison to healthy individuals, with limited benzodiazepines allowed as concomitant psychotropics in order to control their possible side-effects.

The study had a cross-sectional design and, besides blood testing for measuring vitamin D levels, it followed the observational approach. The Ethics Committee of the Clinical Centre “Kragujevac”, Kragujevac, Serbia, approved the research and all subjects signed the informed consent for participation in the study. The study sites included the departments of psychiatry, clinical biochemistry and clinical pharmacology of the hospital.

Our previous research provided the basis for sample size calculation data about the proposed significance between group difference of 25(OH) serum concentrations and their variability (7). Using appropriate software (www.gpower.hhu.de), with $\alpha = 0.05$, study power of 0.8 and other necessary inputs as well as the corrective increase for presumed non-parametric data distribution we estimated total study sample of at least 50 people, 25 in each group. We finally included a total of 56 adult subjects of both genders who were allocated to two groups: 26 patients with mental illnesses taking

* Corresponding author: e-mail: piki@medf.kg.ac.rs

antipsychotic medication (the experimental group) and 30 healthy individuals (the control group). The patients had only one diagnosis from the group of psychotic disorders (World Health Organization International Classification of Diseases version 10, codes F20). The antipsychotic drugs had been the foundation of the treatment with only limited uses of benzodiazepines allowed to enhance sedative, anxiolytic effects. The use of antidepressants, mood stabilizers, cognitive enhancers, and other psychotropic drugs was an exclusion criterion. The drug treatment for a concomitant somatic disease in stable phases or stages was allowed within both study groups.

The semi-structured questionnaire for the assessment of vitamin D status was designed based on the previous studies in the field and the study was conducted within the same geographical area (7-8). Other data were extracted from the patients' medical files or were obtained through an interview in case of healthy subjects. The blood samples were obtained from May to June 2016 which is a season with adequate and approximately the same sunshine exposure. The serums were sent to the hospital laboratory where the vitamin D (in 25(OH)D form), calcium, phosphorus, magnesium, sodium, and potassium concentrations were determined by using

Table 1. Characteristics of study subjects and the status of vitamin D and bone minerals.

Variable	Antipsychotic group (n = 26)	Control group (n = 30)	Statistics
Male gender	12 (46.2)	12 (40.0)	p = 0.642
Age (years)	50.4 (11.9)	49.2 (14.6)	p = 0.986
Body mass index (kg/m ²)	25.3 (4.3)	25.7 (4.0)	p = 0.925
Urban inhabitancy	21 (80.8)	30 (100)	p = 0.017
Higher education*	3 (11.5)	20 (66.7)	p < 0.001
Good life condition*	6 (23.1)	30 (100)	p < 0.001
Smoking	18 (69.2)	9 (30)	p = 0.008
Coffee consumption	13 (50.0)	5 (16.7)	p = 0.012
Physical activity	13 (50.0)	30 (100)	p < 0.001
Sedentary life-style	20 (76.9)	0 (0)	p < 0.001
Meat consumers	22 (84.6)	30 (100)	p = 0.040
Fish consumers	13 (50.0)	27 (90.0)	p = 0.001
Eggs consumers	24 (92.3)	19 (63.3)	p = 0.012
Bread consumption (g/day)	341.7 (158.6)	185.8 (151.9)	p < 0.001
Sun exposure (> 60 min/day)*	9 (34.6)	15 (50.0)	p = 0.031
Arterial hypertension	5 (19.2)	6 (20.0)	p = 0.942
Previous bone fracture	0 (0)	1 (3.3)	p = 1.000
Serum 25(OH)D (ng/mL) ¹	11.2 (8.0, 8.4, 2.9, 30.4)	19.4 (9.1, 15.8, 7.6, 43.6)	p < 0.001
Deficiency/ Insufficiency/ Sufficiency of vitamin D	22 (84.6)/ 3 (11.5)/ 1 (3.9)	19 (63.3)/ 5 (16.7)/ 6 (20.0)	p = 0.128
Serum 25(OH)D in patients with deficiency (ng/mL) ¹	8.4 (4.4, 8.1, 2.9, 19.1)	13.7 (3.2, 13.8, 7.6, 19.4)	p < 0.001
Serum 25(OH)D in patients with insufficiency (ng/mL) ¹	25.7 (3.8, 27.3, 21.4, 28.4)	22.4 (1.4, 22.2, 20.9, 24.6)	p = 0.393
Serum 25(OH)D in patients with sufficiency (ng/mL) ¹	30.4 (n.a.)	34.9 (4.9, 33.8, 30.6, 43.6)	p = 0.286
Serum calcium (mmol/L) ²	2.40 (0.12)	2.40 (0.11)	p = 0.859
Serum magnesium (mmol/L) ²	0.79 (0.11)	0.90 (0.05)	p < 0.001
Serum phosphorous (mmol/L) ²	1.08 (0.25)	1.11 (0.17)	p = 0.896

Numbers represent the frequency (percent), ¹the mean (standard deviation, median, minimum, maximum) and ²the mean (standard deviation); *≥2 categories: n.a.-not applicable, due to a single observation

Figure 1. The serum concentrations of 25(OH)D in patients taking antipsychotic drugs (n = 26) and in healthy, control subjects (n = 30)

"Cobas e601" analyzer (Roche Diagnostics, Mannheim, Germany) and "Beckman Coulter AU 680" biochemical analyzers, as appropriate. Vitamin D measurements were performed using the manufacturer's reagent testing kit (electrochemiluminescence binding assay), providing regular internal and external controls according to the laboratory quality assurance procedures.

The vitamin D status types were defined as: deficiency (< 20 ng/mL), insufficiency (20-29.9 ng/mL) and sufficiency (> 30 ng/mL) (9). Statistical analyses of collected data included testing of sample distribution for normality (Normal Q-Q Plot, Histogram, Kolmogorov-Smirnov test, Shapiro-Wilk test), the measures of descriptive statistics as well as Wilcoxon rank sum test, Pearson χ^2 test and Fisher exact test for analysing the differences between study groups. The level of probability for statistical significance was established at $p < 0.05$. Data processing and analysis were done in the statistical program R – version 3.1.1 (2014-07-10). Demographic and other clinical variables in study subjects are presented in detail in Table 1. There were 16 inpatients and 10 outpatients in the antipsychotic group. The mean duration of their primary mental illness was 15.7 (9.5) years (median 18, range 1-35). The most frequently prescribed antipsychotic drug was haloperidol (in 16 patients) followed by clozapine (7), olanzapine (7), risperidone (5), chlorpromazine (3), fluphenazine (2) and

aripiprazole (1). The mean number of antipsychotic drugs per patient was 1.6 (from 1 to 3). Only allowed concomitant psychotropic medications in patients included benzodiazepines and similar drugs such as lorazepam (in 14 patients), zolpidem (7), diazepam (5), bromazepam (2) and midazolam (2). The arterial hypertension was the most frequent somatic disease in subjects of both study groups and other chronic illnesses were diabetes mellitus type 2 in three patients with psychosis and thyroid disease and osteoporosis in two healthy subjects.

The analysis of the data confirmed that there was a statistically significant difference between study groups in vitamin D serum concentrations (Figure 1) (Table 1). The patients taking antipsychotics had significantly lower vitamin D serum levels than healthy subjects, in both the overall study sample ($n = 56$, $p < 0.001$) and the subgroup of people with the deficiency ($n = 41$, $p < 0.001$). Some socio-demographic and most of the habitual and dietary characteristics that might directly or indirectly impact vitamin D status were statistically different between the study groups (Table 1). However, a multivariable analysis was not performed due to the limited sample size.

The results presented in this paper in addition to other reliable evidence confirm that individuals suffering from psychotic disorders who take antipsychotic drugs are a vulnerable population group for developing inadequate vitamin D serum

concentrations. The patients who participated in our study used benzodiazepines but we are currently unaware of any valid data about the possible influence of this drug class on vitamin D metabolism in humans. Some subjects took antihypertensive medications but the proportion of people with arterial hypertension was small and almost the same in both study groups. Therefore, if the drugs contribute to lower serum levels of 25(OH)D their impact was present in both study groups so antipsychotics remain the only agents for the causative consideration.

On the other hand, our study notes significant differences between the study groups in some lifestyle and dietary habits which could influence vitamin D status. Our previous research has proved that the use of clozapine increases the risk for vitamin D deficiency and that physical activity, exercising and vitamin D-rich food have a protective role (10). A serious or insufficiently controlled psychotic illness is very likely associated with poor socio-economic status and lifestyle habits which alone increase the risk for vitamin D disturbances. However, only a few among the numerous factors investigated in the previously published studies unambiguously correlate with vitamin D levels in people with psychosis (1). Moreover, the evidence about the significance of vitamin D status for normal brain development and functions has accumulated over the years (11-12). The novel study has revealed that low vitamin D blood levels are associated with outbreaks of the first schizophrenia episodes (13). Therefore, vitamin D deficiency could either precede or contribute (or both) to the structural brain damage and functional neuronal disturbances which occur in patients with psychotic illnesses (14).

In our study the serum 25(OH)D concentrations were, in general, low in both the patients and the control subjects. The design of our research precluded a more comprehensive analysis for providing the answer to why many healthy people in our research did not have sufficient vitamin D serum levels during the sunshine period. According to our knowledge, there were no studies published in recent years which investigated 25(OH)D serum concentrations in our country in order to reveal the current vitamin D status for healthy people in a large sample. Yet, some studies which included the postmenopausal women and the students, measuring 25(OH)D serum concentrations during sunshine months, also found a very high frequency of vitamin D deficiency in those, apparently healthy subjects (15, 16). Nevertheless, we are unable to make any conclusion about vitamin D status on the population level at present as the matter was outside the scope of our research.

The inability of proving the causal relationships between antipsychotic use and vitamin D deficiency probably constitutes one of the major limitations of our study. Other investigators in the field also used comparative, cross-sectional design for explorative purposes of vitamin D status in the diseased and the healthy people; however, well-known methodological weaknesses of this study type precludes more sound conclusion about the causality at the moment (17, 18). This issue and other possible study limitations (e.g. role of putative, confounders and their interactions with individual antipsychotics) have to be addressed in further investigations.

In conclusion, patients with psychoses taking antipsychotics have, in comparison with healthy individuals, a higher probability for inadequate serum levels of 25(OH)D. However, the true nature of the relations between the disease, disturbances, antipsychotic drugs, and other plausible contributors are currently unknown. Taking into account the significance and the scope of medical and public health issues related to mental disorders, the further research into nutrition and pharmacotherapy is needed in near future in order to finally resolve the issues of potential drug causalities.

Acknowledgments

Authors thank the Faculty of Medical Science University of Kragujevac for the support with the junior research grant JP 13-14.

Conflict of interest

All authors have no conflicts of interest.

REFERENCES

1. Adamson J., Lally J., Gaughran F., Krivoy A., Allen L. at al.: *Psychiatry Res.* 249, 78 (2017).
2. Chu F., Ohinmaa A., Klarenbach S., Wong Z.W., Veugelers P.: *Nutrients* 9, 1116 (2017).
3. Krivoy A., Onn R., Vilner Y., Hochman E., Weizman S. at al.: *EBioMedicine* 26, 138 (2017).
4. Milovanovic D.R., Stanojevic Pirkovic M., Zivancevic Simonovic S., Matovic M., Djukic Dejanovic S. at al.: *Psychiatry Investig.* 13, 89 (2016).
5. Lee S.H., Hsu W.T., Lai C.C., Esmaily-Fard A., Tsai Y.W. at al.: *Osteoporos. Int.* 28, 1167 (2017).
6. Hategan A., Bourgeois J.A.: *Psychosomatics* 54, 606 (2013).

7. Stanojević Pirković M.: Risk factors for disturbances of bone tissue homeostasis in patients with psychotic disorders, PhD Thesis, Faculty of Medical Sciences University of Kragujevac, Kragujevac (in Serbian) 2012.
8. Milovanovic O.: Population pharmacokinetics of 25-hydroxyvitamin D in students, PhD Thesis, Faculty of Medical Sciences University of Kragujevac, Kragujevac (in Serbian) 2014.
9. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A. et al.: J. Clin. Endocrinol. Metab. 96, 1911 (2011).
10. Ristic S., Zivanovic S., Milovanovic D.R., Janjic V., Djokovic D. et al.: J. Nutr. Sci. Vitaminol. 63, 85 (2017).
11. Cui X., Gooch H., Petty A., McGrath J.J., Eyles D.: Mol. Cell. Endocrinol. 453, 131 (2017).
12. Anjum I., Jaffery S.S., Fayyaz M., Samoo Z., Anjum S.: Cureus 10, e2960 (2018).
13. Firth J., Carney R., Stubbs B., Teasdale S.B., Vancampfort D. et al.: Schizophr. Bull. 44, 1275 (2018).
14. Kočovská E., Gaughran F., Krivoy A., Meier U.C.: Psychiatry 8, 47 (2017).
15. Vuceljic M., Ilic-Stojanovic O., Lazovic M., Grajic M.: Vojnosanit Pregl. 69, 243 (2012).
16. Milovanovic O.Z., Milovanovic J.R., Djukic A., Matovic M., Lucic A.T. et al.: Acta Pol. Pharm. 72, 213 (2015).
17. Workineh M., Mathewos B., Moges B., Gize A., Getie S. et al.: Arch. Public Health 75, 25 (2017).
18. Grimes D.A., Schulz K.F.: Lancet 359, 145 (2002).

Received: 18.11.2018